EUROPEAN HEMATOLOGY ASSOCIATION

24th Congress of EHA

 

June 13-16, 2019 Amsterdam
Close
N. Poster
Poster title
Applicant name
Status
  163-PF TARGETING LYSOSOMES AS A POTENTIAL THERAPEUTIC APPROACH FOR T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA Antonia Mulet Received Received
  174-PF GERIATRIC ASSESSMENT-BASED TREATMENT OF ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS. RESULTS OF THE GIMEMA LAL1104 PROTOCOL Sabina Chiaretti Received Received
  179-PF DIFFERENT IMPACT OF BCR BREAKPOINT ON THE OUTCOME OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION FROM DIFFERENT GRAFT SOURCE FOR PHALL IN THE ERA OF TKI Satoshi Nishiwaki Received Received
  182-PF CLINICOBIOLOGIC CHARACTERISTICS AND OUTCOME OF ELDERLY FRAIL PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA INCLUDED IN A SPECIFIC PROTOCOL (ALL-07FRAIL) Jose Maria Ribera Santasusana Received Received
  184-PF EFFICACY OF CONSOLIDATION CHEMOTHERAPY FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WHO ACHIEVED COMPLETE REMISSION BY FIRST COURSE OF REMISSION INDUCTION THERAPY. Akio Shigematsu Received Received
  204-PF TARP AS IMMUNOTHERAPEUTIC TARGET IN AML EXPRESSED IN THE LSC COMPARTMENT BARBARA DEPRETER Received Received
  206-PF DUAL TARGETING OF LYSOSOMES AND MITOCHONDRIA BY ANTIHISTAMINES TO ERADICATE LEUKEMIC CELLS Josep Maria Cornet-Masana Received Received
  211-PF MITOCHONDRIAL PRIMING OF BLASTS, BUT NOT LSC, PREDICTS SURVIVAL IN OLDER AML PATIENTS TREATED INTENSIVELY INDEPENDENTLY OF ONCOGENETICS: A STUDY ON THE ALFA 1200 TRIAL Reinaldo Dal Bello Received Received
  212-PF NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS Nicholas Short Received Received
  216-PF ROLE OF MEASURABLE RESIDUAL DISEASE (MRD) IN REDEFINING COMPLETE RESPONSE (CR) IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): RESULTS FROM THE PETHEMA-FLUGAZA PHASE III CLINICAL TRIAL Bruno Paiva Received Received
  221-PF MUTATIONAL PROFILE BY NGS COMBINED WITH EX VIVO DRUG SENSITIVITY PROFILE IMPROVE PREDICTION OF AML PATIENT OUTCOME Esther Onecha Received Received
  224-PF NOVEL ICMT INHIBITOR AS POTENTIAL TREATMENT OF RAS-DRIVEN ACUTE MYELOID LEUKEMIA Miguel Gallardo Received Received
  228-PF DIAGNOSTIC VALUE OF PU.1 LOCALIZATION IN ACUTE MYELOID LEUKEMIA WITH MUTATED NPM1 Giulia Pianigiani Received Received
  235-PF COMPREHENSIVE GENETIC TEST TO DETECT ALL GENE FUSIONS IN HEMATOLOGICAL MALIGNANCIES? Eva van den Berg-de Ruiter Received Received
  250-PF HNRNP K OVEREXPRESSION INDUCE NUCLEOLAR STRESS, A HALLMARK OF ACUTE MYELOID LEUKEMIA Pedro Aguilar-Garrido Received Received
  253-PF SAFETY AND RESOURCE UTILIZATION FOLLOWING EARLY HOSPITAL DISCHARGE AFTER INDUCTION CHEMOTHERAPY FOR ACUTE MYELOID LEUKEMIA (AML): A 4-YEAR RETROSPECTIVE ANALYSIS Nicholas Howard Received Received
  258-PF REAL-WORLD DATA ON DOSE-RELATED EFFECT OF ARSENIC TRIOXIDE IN THE RELAPSE OF ACUTE PROMYELOCYTIC LEUKEMIA Huaiyu Wang Received Received
  264-PF TREATMENT INTENSIFICATION WITH FLAG-IDA MAY IMPROVE DISEASE CONTROL IN YOUNGER PATIENTS WITH SECONDARY AML WHICH MANIFESTS ITSELF WITH LONGER FOLLOW-UP: LONG-TERM ANALYSIS OF THE MRC AML15 TRIAL Robert Hills Received Received
  267-PF RISK ASSESSMENT OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH ACUTE LEUKEMIA AND CONCOMITANT ISCHEMIC HEART DISEASE Tetiana Lymanets Received Received
  268-PF DECIPHERING THE ABERRANT IMMUNE MICROENVIRONMENT IN ACUTE MYELOID LEUKEMIA DEVELOPMENT AND ITS ROLE IN CHEMOTHERAPY RESPONSE AND RELAPSE Heng Mei Received Received
  271-PF USING NEXT-GENERATION SEQUENCING TO PREDICT RESPONSE TO SALVAGE CHEMOTHERAPY WITH HIGH DOSE CYTARABINE AND MITOXANTRONE IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA PATIENTS Jonathan Canaani Received Received
  286-PF EARLY ADMISSION IN INTENSIVE CARE UNIT IS ASSOCIATED WITH LOWER MORBIDITY AND MORTALITY IN ACUTE MYELOID LEUKEMIA WITH HYPERLEUKOCYTOSIS: A RETROSPECTIVE ANALYSIS. Nathan Mottal Received Received
  290-PF INCIDENCE AND PROGNOSTIC IMPACT OF A BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM-LIKE PHENOTYPE IN AML PATIENTS. Fabio Guolo Received Received
  304-PF Osteoporosis And Low-energy Fractures After Treatment For Lymphoma With Corticosteroid-containing Immunochemotherapy: A Danish Nationwide Cohort Study Joachim Bch Received Received
  311-PF ISOLATED PRIMARY ADRENAL LYMPHOMA (IPAL) - AN EMERGING LYMPHOMA ENTITY? RESULTS OF A RETROSPECTIVE MULTICENTER STUDY Fatemeh Majidi Received Received
  325-PF REAL - LIFE DATA ON ROMIDEPSIN TREATMENT FOR RELAPSED AND REFRACTORY PERIPHERAL AND CUTANEOUS T-CELL LYMPHOMA - A MULTI-CENTER NATIONAL OBSERVATIONAL STUDY shai shimony Received Received
  333-PF RISK OF BLEEDING COMPLICATIONS AND ATRIAL FIBRILLATION ASSOCIATED WITH IBRUTINIB TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS Luca Pellegrini Received Received
  337-PF ALRN-6924, A DUAL INHIBITOR OF MDMX AND MDM2 THAT CAUSES MINIMAL THROMBOCYTOPENIA IN PATIENTS, DISRUPTS DIFFERENT STAGES OF THROMBOPOIESIS COMPARED TO MDM2-ONLY INHIBITION Allen Annis Received Received
  344-PF HIGH FREQUENCY ASXL1 MUTATIONS AND MULTIPLE SUBCLONAL PIGA MUTATIONS ARE OBSERVED IN CELLULAR AND CELL-FREE DNA IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA Georgie Ryland Received Received
  357-PF A NOVEL REFINED PROGNOSTIC MODEL FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMBINING IGH TRANSLOCATIONS AND NEXT-GENERATION SEQUENCING Claudia Perez Received Received
  359-PF TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT Luciana Cafforio Received Received
  365-PF PROGNOSTIC IMPLICATIONS OF IGHV GENE REARRANGEMENTS WITH BORDERLINE PERCENTAGE OF MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS Ilaria Del Giudice Received Received
  368-PF DYSREGULATION OF BACH2 AND FOXP1 GENES IN T AND B CELLS IS MORE PRONOUNCED IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS COMPARED TO AGED-MATCHED HEALTHY DONORS WITH AN IMPACT ON SURVIVAL DOMINIQUE BRON Received Received
  370-PF SIGNAL-OMICS ANALYSIS OF THE IMPACT OF THERAPY ON BCR SIGNALLING IN CHRONIC LYMPHOCYTIC LEUKAEMIA. Adam Linley Received Received
  373-PF IMPACT OF ATM ALTERATIONS ON CHRONIC LYMPHOCYTIC LEUKEMIA IN GENERAL PRACTICE IN THE AREA OF NEXT GENERATION SEQUENCING Michel Ganard Received Received
  376-PF DIFFERENTIAL GENOMIC AND TRANSCRIPTOMIC EVENTS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION OF CHRONIC LYMPHOCYTIC LEUKEMIA Jenny Klintman Received Received
  379-PF PREVALENCE AND INCIDENCE OF CARDIOVASCULAR DISEASE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A NATION-WIDE POPULATION-BASED STUDY. Karin Larsson Received Received
  380-PF SINGLE CELL ABNORMALITIES ON CLASSIC G-BANDING ANALYSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA: CLINICOBIOLOGICAL FEATURES AND PROGNOSTIC VALUE Michail Iskas Received Received
  382-PF PROGNOSTIC MODELS FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN EXEMPLAR SYSTEMATIC COCHRANE REVIEW AND META-ANALYSIS (PRELIMINARY RESULTS) Nina Kreuzberger Received Received
  388-PF HAT-PCR IS MORE SENSITIVE THAN FLOW FOR QUANTIFYING MRD IN CHRONIC LYMPHOCYTIC LEUKEMIA Alexander Morley Received Received
  391-PF INFLUENCE OF ATORVASTATIN THERAPY ON GALECTIN-3, VE-CADHERIN, AND CARDIOVASCULAR RISK IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Borys Samura Received Received
  402-PF PECULIARITIES OF THE EXPRESSION OF KI-67 AND CD34 HEMOPOIETIC PRECURSOR CELLS IN PB AND BM OF CML PATIENTS WITH THE DIFFERENT RESPONSES TO IMATINIB AND NILOTINIB THERAPY Tetiana Perekhrestenko Received Received
  420-PF RESULTS OF A PROSPECTIVE MULTICENTER STUDY ON PRO-ATHEROTHROMBOTIC EFFECT INDUCED BY TYROSINE-KINASE INHIBITORS FOR FIRST-LINE TREATMENT OF CML PTS (KIARO TRIAL) Anna Sicuranza Received Received
  422-PF THE LONG-TERM TREATMENT RESULTS ACCORDING TO THE MULTICENTER EUTOS ELN POPULATION-BASED STUDY (EUTOS-PBS) IN RUSSIAN PATIENTS WITH CHRONIC MYELOID LEUKEMIA Olga Lazareva Received Received
  423-PF SAFETY OF IMATINIB AND ITS GENERICS IN CHRONIC MYELOID LEUKEMIA: A SUBANALYSIS OF POLISH IMATINIB GENERICS REGISTRY AFTER THREE YEARS OF OBSERVATION Joanna W&261;c&322;aw Received Received
  427-PF FOSTAMATINIB, A SPLEEN TYROSINE KINASE INHIBITOR, FOR THE TREATMENT OF WARM ANTIBODY AUTOIMMUNE HEMOLYTIC ANEMIA: INITIAL RESULTS OF THE OPEN-LABEL EXTENSION PERIOD OF THE SOAR PHASE 2 STUDY Leslie Todd Received Received
  435-PF A FLEXIBLE THERAPEUTIC STRATEGY FOR LEUKEMIA USING EX-VIVO EXPANDED T CELLS COMBINED WITH BISPECIFIC ANTIBODIES Josee Golay Received Received
  436-PF GMP MANUFACTURING OF ALLOGENEIC CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) CYTOKINE INDUCED KILLER (CIK) CELLS WITH SLEEPING BEAUTY (SB) TRANSPOSON FOR ADOPTIVE IMMUNOTHERAPY Chiara F Magnani Received Received
  445-PF INHIBITION OF ACUTE LYMPHOBLASTIC AND MYELOID LEUKEMIAS BY NOVEL CHIMERIC MOUSE-HUMAN MONOCLONAL ANTIBODIES AGAINST ANTIGEN PRAME Andrey Misyurin Received Received
  453-PF TRANSCRIPTOME-PROTEOME CORRELATION IN HUMAN HEMATOPOIETIC STEM AND PROGENITOR CELLS Fabienne Meier-Abt Received Received
  459-PF ANGELICA SINENSIS POLYSACCHARIDE MAINTAINS THE FUNCTION OF HEMATOPOIETIC STEM CELLS BY REGULATING THE TREG/TH17 RATIO AND THEREBY INDUCES ANTI-MITOCHONDRIAL APOPTOSIS IN APLASTIC ANEMIA xing cui Received Received
  464-PF DEFERASIROX DRIVES ROS-MEDIATED DIFFERENTIATION AND INDUCES INTERFERON-STIMULATED GENES EXPRESSION IN HEALTHY HEMATOPOIETIC STEM/PROGENITOR CELLS AND IN LEUKEMIA CELLS Tiziana Tataranni Received Received
  467-PF NEW MOLECULES INSPIRED ON MICROBIOTA METABOLITES TARGETING ACUTE MYELOID LEUKEMIA CELLS Sergio Algar Received Received
  470-PF FIVE-YEAR SURVIVAL AND DURABILITY RESULTS OF THE BEGEV REGIMEN FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA Francesca Ricci Received Received
  471-PF DEPRESSION AND ANXIETY IN HODGKIN LYMPHOMA SURVIVORS: A DANISH NATIONWIDE COHORT STUDY OF 896 PATIENTS Andreas vlisen Received Received
  473-PF PEDIATRIC HODGKIN LYMPHOMA: DISPARITIES IN SURVIVAL BY RACE Karishma Khullar Received Received
  485-PF PARTIAL RESPONSE OR BETTER AT 6 MONTHS IS PROGNOSTIC OF PROGRESSION-FREE SURVIVAL IN PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB Jorge Castillo Received Received
  489-PF BR VS RCHOP AS INITIAL TREATMENT FOR ADVANCED STAGE FOLLICULAR LYMPHOMA: A MATCHED-PAIR ANALYSIS PAOLO STRATI Received Received
  490-PF PRESENCE OF BRAFV600E MUTATION IN CHILDHOOD LCH CORRELATES WITH MULTISYSTEM DISEASE AND A POOR SURVIVAL PRATEEK BHATIA Received Received
  491-PF RITUXIMAB is an effective therapy for Cold Agglutinin Disease but need to be used cautiously Pierre Daufresne Received Received
  492-PF RESPONSE AND SURVIVAL OUTCOMES OF WALDENSTROM MACROGLOBULINEMIA PATIENTS ON IBRUTINIB THERAPY ON AND OFF CLINICAL TRIAL Jorge Castillo Received Received
  493-PF TP53 STATUS IN MANTLE CELL LYMPHOMA (MCL) - A 10 YEAR SINGLE CENTER EXPERIENCE Ezzat Elhassadi Received Received
  501-PF HOMOZYGOUS I281T MUTATION IN HJV CAUSING INDOLENT JUVENILE HEMOCHROMATOSIS WITH A MIDDLE TO LATE ONSET Akiyoshi Takmai Received Received
  504-PF LONG-TERM SEQUENTIAL DEFERIPRONE AND DEFERASIROX THERAPY INTRANSFUSION-DEPENDENT THALASSEMIA PATIENTS: A PROSPECTIVE CLINICAL TRIAL Angela Vitrano Received Received
  507-PF THE HEPCIDIN-ERYTHROFERRONE AXIS AND ITS RELATIONSHIP WITH ERYTHROPOIESIS IN DIFFERENT TYPES OF ANEMIA Rafael Del Orbe Barreto Received Received
  516-PF ESTROGEN BETA RECEPTOR: A NEW TARGET FOR DIFFUSE LARGE B-CELL LYMPHOMA. Myra Langendonk Received Received
  521-PF CHOP TREATMENT ENHANCES DEPENDENCY ON BCL-2, MCL-1 AND BCL-XL IN DIFFUSE LARGE B-CELL LYMPHOMA Mathilde de Jong Received Received
  526-PF STRUCTURAL AND FUNCTIONAL VARIABILITY OF THE TUMOR B-CELL RECEPTOR INDICATES A ROLE FOR ENVIRONMENTAL INFLUENCES ON BEHAVIOR OF MANTLE CELL LYMPHOMAS David Dutton Received Received
  527-PF PROTEIN KINASE CK1 ALPHA INACTIVATION CAUSES MANTLE CELL LYMPHOMA GROWTH ARREST AND SYNERGISTICALLY ENHANCES IBRUTINIB CYTOTOXICITY Francesco Piazza Received Received
  532-PF INTEGRATED PROFILING OF DNA METHYLATION AND MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES. Suguru Morimoto Received Received
  543-PF PROMOTER METHYLATION OF TUMOR SUPPRESSOR GENES ON THE SHORT ARM OF CHROMOSOME 1 IN MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA Naoki MORI Received Received
  563-PF MARROW INFILTRATING T-REGULATORY CELLS ASSOCIATE WITH PD-1 EXPRESSING CD4 EFFECTOR CELLS AND INFERIOR OUTCOMES IN PATIENTS UNDERGOING NOVEL-AGENT REGIMENS FOR NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) Nouf Alrasheed Received Received
  565-PF MMBMSCS INDUCE IMMUNOSENESCENT NAVE CD4 T-CELLS THROUGH THE NOVEL INTERCELLULAR COMMUNICATION TUNNELING NANOTUBES Yadan Wang Received Received
  566-PF INCREASE OF MITOCHONDRIAL ACTIVITY CONTRIBUTES TO RELAPSE IN MULTIPLE MYELOMA, A NOVEL THERAPEUTIC OPPORTUNITY Alejandra Ortiz-Ruiz Received Received
  572-PF ANALYSES OF EXPRESSION LEVELS, MUTATIONS, AND METHYLATION STATUS OF CRBN-RELATED GENES PRE- AND POST-LENALIDOMIDE TREATMENT IN MULTIPLE MYELOMA Takuto Tachita Received Received
  573-PF SINGLE CELL RNA-SEQ REVEALED A RARE ITGA2 EXPRESSING CELL SUBPOPULATION WITH DISTINCT CANCER STEM CELL MARKER SIGNATURE IN MULTIPLE MYELOMA Margaret Ng Received Received
  579-PF TUMOR CIRCULATING PLASMA CELLS DETECTED BY FLOW CYTOMETRIC SINGLE PLATFORM METHOD ARE RELATED TO NEGATIVE PATIENTS CHARACTERISTICS IN MULTIPLE MYELOMA. Paola Omedè Received Received
  586-PF SPARING STEROIDS IN ELDERLY INTERMEDIATE-FIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH A DOSE/SCHEDULE-ADJUSTED RD-R VS. CONTINUOUS RD: RESULTS OF RV-MM-PI-0752 PHASE III RANDOMIZED STUDY Alessandra Larocca Received Received
  607-PF MAINTENANCE WITH WEEKLY CARFILZOMIB IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (IFM 2012-03). Arthur Bobin Received Received
  611-PF MULTIPLE DRUG COMBINATIONS FOR FIRST-LINE TREATMENT IN TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA PATIENTS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS Vanessa Piechotta Received Received
  615-PF IMPACT OF PATIENTS CHARACTERISTICS ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RESULTS FROM THE CHARISMMA STUDY MARTA GRANDE Received Received
  620-PF COMPARISON OF RISS AND IMWG RISK STRATIFICATION GUIDELINES WITH GENE EXPRESSION PROFILE SKY92 IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; RESULTS FROM THE PROMMIS TRIAL Femke de Snoo Received Received
  621-PF REAL WORLD EXPERIENCE IN THE MANAGEMENT OF WALDENSTRMS MACROGLOBULINAEMIA FROM ANALYSIS OF THE RORY MORRISON REGISTRY Joshua Bomsztyk Received Received
  627-PF SERUM CEREBLON LEVELS PREDICT FIVE- YEAR POST LEALIDOMIDE/DEXAMETHASONE (RD) SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS AND CORRELATE WITH DISEASE CHARACTERISTICS. Annita Ioanna Gkioka Received Received
  633-PF PROGNOSTIC VALUE OF KIDNEY BIOPSY INTERSTITIAL FIBROSIS IN REVERSIBILITY OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY DUE TO MYELOMA CAST NEPHROPATHY Evgeniya Kazarina Received Received
  634-PF OUTCOMES OF SALVAGE WITH INFUSIONAL REGIMENS DT-PACE/ESHAP FOR REFRACTORY OR RELAPSED MULTIPLE MYELOMA (MM) Louise Ainley Received Received
  635-PF SERUM ERYTHROPOIETIN IS A PREDICTIVE FACTOR OF RENAL REVERSIBILITY IN RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS Hiroki Kobayashi Received Received
  638-PF Real world data examining the use of Ixazomib, Lenalidomide and Dexamethasone (ILD) and Lenalidomide and Dexamethasone (LD) chemotherapy in Multiple Myeloma Keonwoo Yi Received Received
  642-PF REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE TREATMENT OPTION IN HIGH RISK MYELOMA PATIENTS A SINGLE CENTRE EXPERIENCE Amanda Jurgensen-Rauch Received Received
  657-PF USE OF A NGS MYELOID PANEL TO FIND CLONALITY IN TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA. IDENTIFICATION OF NEW MUTATIONS IN DRIVER GENES Gonzalo Carreno Received Received
  661-PF MOLECULAR PROFILING REVEALS HIGHLY DEREGULATED INSULIN GROWTH FACTOR BINDING PROTEINS IN PATIENTS WITH MYELOFIBROSIS AND RELATED NEOPLASMS Vibe Skov Received Received
  664-PF 46/1 HAPLOTYPE IS ASSOCIATED WITH A HIGHER MONOCYTE/LYMPHOCYTE RATIO IN HEALTHY INDIVIDUALS Gonzalo Carreno Received Received
  665-PF SERUM FERRITIN LEVELS ARE INCREASED IN IDIOPATHIC ERYTHROCYTOSIS BUT REDUCED IN POLYCYTHEMIA VERA Giacomo Biagetti Received Received
  669-PF RUXOLITINIB TREATMENT AND RISK OF B-CELL LYMPHOMAS IN MYELOPROLIFERATIVE NEOPLASMS Chiara Cavalloni Received Received
  670-PF MOLECULAR CLASSIFICATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA WHO DEVELOP RESISTANCE OR INTOLERANCE TO HYDROXYUREA Álvaro Díaz Received Received
  674-PF OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS Francesca Palandri Received Received
  675-PF JAK2V617F AND MPL MUTATIONS ARE ASSOCIATED WITH WORSENED SYMPTOM BURDEN THAN CALR IN THE MYELOPROLIFERATIVE NEOPLASMS: FINDINGS FROM THE MYMPN PATIENT REGISTRY Robyn Scherber Received Received
  676-PF BODY MASS INDEX AND TOTAL SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASMS DISCOVERY OF A U-SHAPED ASSOCIATION Robyn Scherber Received Received
  684-PF ANAGRELIDE MODULATES PROPLATELET FORMATION RESULTING IN DECREASED NUMBER AND INCREASED SIZE OF PLATELETS Naohiro Miyashita Received Received
  686-PF HEALTHCARE RESOURCE IMPLICATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSIS Ximena Cabrera Castellano Received Received
  703-PF LONG-TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM Leslie Todd Received Received
  716-PF CLINICAL IMPACT OF PROGNOSTIC NUTRITIONAL INDEX IN DIFFUSE LARGE B CELL LYMPHOMA Gyeong-Won Lee Received Received
  717-PF QUALITY OF LIFE (QOL), PERSPECTIVES ON TREATMENT AND IMPORTANT OUTCOMES FOR MULTIPLE MYELOMA (MM) PATIENTS AND THEIR CARERS: A MIXED METHODS EVIDENCE SYNTHESIS Keith Stubbs Received Received
  732-PF AN INDEPENDENT OBSERVATIONAL STUDY OF REAL LIFE COSTS OF CARE TO MYELOMA PATIENTS IN THE ERA OF NOVEL THERAPIES Jane Thompson Received Received
  742-PF CEREBRAL OXYGEN METABOLISM MEASUREMENTS WITH MRI IN ADULTS WITH SICKLE CELL DISEASE Lena Vaclavu Received Received
  743-PF PENICILLIN PROPHYLAXIS AND PNEUMOCOCCAL VACCINE USE IN ADULT SICKLE CELL PATIENTS: A RETROSPECTIVE ANALYSIS OF CLINICAL PRACTICE AND OUTCOMES IN OXFORD, UK Ayesha Ejaz Received Received
  745-PF HIGH-DOSE THERAPY AND AUTOLOGOUS TRANSPLANT FOR POEMS SYNDROME: EFFECTIVE, BUT HOW TO OPTIMISE? Oliver Tomkins Received Received
  753-PF IMPACT OF ANTI-THYMOCYTE GLOBULIN DOSES IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR PATIENTS WITH MYELOID NEOPLASM JUN YEB NAM Received Received
  756-PF DONOR UNC-93 HOMOLOG B1 GENETIC VARIATION PREDICTS SURVIVAL OUTCOMES AFTER UNRELATED BONE MARROW TRANSPLANTATION Kaori Uchino Received Received
  757-PF REDUCED INTENSITY CONDITIONING AND AVOIDING USE OF BROAD SPECTRUM ANTIBIOTHERAPY ACTIVE AGAINST GRAM-NEGATIVE BACTERIA MIGHT HAVE A CUMULATIVE IMPACT IN REDUCING INTESTINAL MICROBIOTA MISBALANCE. Nancy Rodriguez Received Received
  766-PF T CELL EXHAUSTION PROFILE (CD4/CD28/PER/GRA CD8/CD28/PER/GRA) IN STEMCELL TRANSPLANTATION, CMV RE ACTIVATIONS AND RESPIRATORY VIRUS INFECTION.CELLULAR DYNAMICS IN THE FIRST 100 DAYS POST SCT Miguel Villanueva Received Received
  775-PF MONOSOMY 7 ALONE OR WITH OTHER CHROMOSOMAL ABNORMALITIES SIGNIFICANTLY AFFECT SURVIVAL OF SECONDARY AML PATIENTS TREATED WITH ALLOGENEIC- SCT Mona Hassanein Received Received
  788-PF DATA FROM THE FRENCH REGISTRY FOR BETA-THALASSEMIA PATIENTS Badens Catherine Received Received
  802-PF ANTICOAGULANT THERAPY IN THROMBOCYTOPENIC PATIENTS WITH BLOOD CANCER AND CATHETER-RELATED VTE: RESULTS FROM A DELPHI CONSENSUS ON PLATELETS COUNT BELOW 50 X 109L Sergio Siragusa Received Received
  813-PF PROFILE OF BLOOD DONORS WITH SEROLOGIC TESTS REACTIVE IN HOSPITAL METROPOLITANO IN QUITO- ECUADOR FROM JANUARY 2016 TO DECEMBER 2018. johanna rojas Received Received
  817-PF INTENSIVE PLAN OF THERAPEUTIC PLASMA EXCHANGE IN PATIENT WITH EXTREME HYPERTRLIGLYCERIDEMIA DUE TO L-ASPARAGINASE IN THE CONTEXT OF SMILE PROTOCOL IN T/NK NASAL LYMPHOMA TREATMENT Eduardo Sobejano Received Received
  914-PS CONDITIONAL MEF2C EXPRESSION IN THE MOUSE THYMUS DRIVES DEVELOPMENT OF T/B-BIPHENOTYPIC LYMPHOID LEUKEMIA/LYMPHOMA Kirsten Canté-Barrett Received Received
  918-PS CIRCRNA DEREGULATION IN B-CELL PEDIATRIC ACUTE LEUKEMIA: THE MLL RECOMBINOME AND BEYOND Stefania Bortoluzzi Received Received
  919-PS ROLE OF CHOROID PLEXUS STROMA IN TUMOUR CHEMORESISTANCE: A SANCTUARY FOR LEUKAEMIA CELLS IN THE CENTRAL NERVOUS SYSTEM Lidia Martínez Received Received
  921-PS INACTIVATION OF SH2B3 THROUGH CN-LOH 12Q IS UNIQUELY ASSOCIATED WITH B-CELL PRECURSOR ALL WITH IAMP21 OR OTHER CHROMOSOME 21 GAIN. Paul Sinclair Received Received
  933-PS DISCOVERING PATHWAYS INVOLVED IN RESISTANCE TO INDUCTION THERAPY IN T-ALL TO TREAT REFRACTORY AND RELAPSED DISEASE Melanie Beckett Received Received
  935-PS APPLICABILITY OF DROPLET DIGITAL PCR (DDPCR) FOR MINIMAL RESIDUAL DISEASE MONITORING (MRD) IN PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA Sabina Chiaretti Received Received
  941-PS ANTI-CD19 CAR-T THERAPY BRIDGING TO ALLO-HSCT IMPROVES LONG-TERM OUTCOME OF B-ALL PATIENTS WITH HIGH LEUKEMIA BURDEN OR POOR PROGNOSTIC MARKERS Heng Mei Received Received
  942-PS CD19 MUTATION FREQUENCY AFTER BLINATUMOMAB TREATMENT IS LOWER THAN AFTER CAR T-CELLS TREATMENT Michaela Kotrova Received Received
  958-PS IMPROVING THE SAFETY OF CAR-T CELL THERAPY BY CONTROLLING CRS-RELATED COAGULOPATHY Heng Mei Received Received
  963-PS ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: DOES MINIMAL RESIDUAL DISEASE BEFORE TRANSPLANTATION MATTER FOR LONG TERM OUTCOME? Irati Ormazabal Velez Received Received
  982-PS THE ROLE OF STAT3 ISOFORMS IN ACUTE MYELOID LEUKEMIA Dagmar Stoiber Received Received
  991-PS CA-4948, AN IRAK4/FLT3 INHIBITOR, SHOWS ANTILEUKEMIC ACTIVITY IN MOUSE MODELS OF FLT3 WILD-TYPE AND FLT3 MUTATED ACUTE MYELOID LEUKEMIA (AML) Robert Booher Received Received
  992-PS MSI2 REGULATES BACH1/BRIP1 THUS AFFECTING THE OXIDATIVE STRESS RESPONSE Jessica Hoell Received Received
  996-PS TCF4 IS IMPORTANT FOR MUTANT RUNX1-MEDIATED CELL IMMORTALIZATION AND PREDICTS OUTCOME IN ACUTE MYELOID LEUKEMIA Florentien in t Hout Received Received
  1006-PS INHIBITORS OF HOXA9 LEUKEMOGENIC TRANSCRIPTION FACTOR ARE EFFICIENT ON HUMAN AML CELL MODELS BUT NOT ON NORMAL HUMAN BONE MARROW CD34 HEMATOPOIETIC CELLS Marie-Helene David-Cordonnier Received Received
  1016-PS COMPARATIVE ANALYSES OF LEUKEMIC BLAST PHENOTYPE AND MUTANT/WT EXPRESSION RATIO IN FLT3-ITD ACUTE MYELOID LEUKEMIAS Dan-Sebastian Soare Received Received
  1028-PS ALLG APML5: A COMPARATIVE BIOAVAILABILITY STUDY OF ENCAPSULATED ORAL ARSENIC TRIOXIDE AND INTRAVENOUS ARSENIC TRIOXIDE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA UNDERGOING CONSOLIDATION THERAPY Harry Iland Received Received
  1032-PS SURVIVAL FROM ACUTE MYELOID LEUKEMIA HAS SINCE 1997 IMPROVED ONLY IN MALES AGED 50-75 YEARS A SWEDISH POPULATION-BASED STUDY Gunnar Juliusson Received Received
  1037-PS FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS Iphigenia Koumenis Received Received
  1040-PS DETECTION OF MRD MAY PREDICT THE OUTCOME OF PATIENTS WITH ACUTE MYELOID LEUKEMIA WITH BIALLELIC CEBPA MUTATIONS Jing Wamg Received Received
  1046-PS FLT3 LIGAND PLASMA LEVELS HAVE NO IMPACT ON OUTCOMES AFTER ALLOTRANSPLANT IN ACUTE LEUKEMIA. Pierre Peterlin Received Received
  1047-PS EFFICACY AND SAFETY EVALUATION OF DIFFERENT DOSES OF ANTHRACYCLINES IN THE INDUCTION THERAPY FOR NEWLY DIAGNOSED ACUTE PROMYELOCYTIC LEUKEMIA Xiaohui Hu Received Received
  1050-PS MARKER CHROMOSOME IS A STRONG POOR PROGNOSIS FACTOR AFTER ALLOGENEIC HSCT FOR AML PATIENTS Kyoko Fuse Received Received
  1054-PS INTENSIFIED CONDITIONING WITH FLUDARABINE/MELPHALAN PLUS TOTAL BODY IRRADIATION VERSUS FLUDARABINE/MELPHALAN ALONE FOR ACUTE MYELOID LEUKEMIA Sarah Lindner Received Received
  1056-PS ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROME WITH CHROMOSOME 17 ABNORMALITIES AND LONG-TERM OUTCOMES WITH OR WITHOUT HEMATOPOIETIC STEM CELL TRANSPLANTATION GHULAM REHMAN MOHYUDDIN Received Received
  1057-PS INDUCTION WITH FLUGA SCHEME AND MAINTENANCE WITH DECITABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA OF 65 YEARS AND OLDER Sofía Costa Received Received
  1077-PS EVENT FREE SURVIVAL AT 12 MONTHS AND 24 MONTHS AS PREDICTORS FOR OUTCOME OF SYSTEMIC PERIPHERAL T CELL LYMPHOMA: ANALYSIS OF NATIONWIDE THAI LYMPHOMA STUDY GROUP Kitsada Wudhikarn Received Received
  1098-PS ADULT ONSET HEREDITARY THROMBOTIC THROMBOCYTOPENIC PURPURA WITH A NOVEL ADAMTS13 MUTATION Julian Freue Received Received
  1114-PS PATIENTS WITH GAUCHER DISEASE SHOW AN IMMUNE-DYSREGULATION PATTERN SECONDARY TO A DEFECT OF APOPTOSIS Maurizio Miano Received Received
  1119-PS PNH CLONE SIZE BY FLOW CYTOMETRY AND ITS CORRELATION TO PIG GENE MUTATION Dajeong Jeong Received Received
  1120-PS IRON MOBILIZATION IN A REAL LIFE COHORT OF APLASTIC ANEMIA PATIENTS TREATED WITH ELTROMBOPAG Francesca Cavallaro Received Received
  1121-PS ABSENCE OF GPI-NEGATIVE CELLS AT DIAGNOSIS AND LOW NEUTROPHIL COUNT 2 MONTHS AFTER ATGAM BASED TREATMENT ARE ASSOCIATED WITH LOWER 6-MONTH RESPONSE RATE IN ADULTS WITH (VERY) SEVERE APLASTIC ANEMIA Jennifer Tjon Received Received
  1128-PS FUNGI INFECTION VERSUS IBRUTINIB TREATMENT: ROLE OF NURSE-LIKE CELLS DURING ASPERGILLUS FUMIGATUS INFECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS Stefania Fiorcari Received Received
  1141-PS PROTEOMICS MARKERS PROGNOSTIC FOR OUTCOME OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER TREATMENT; RESULTS FROM THE HOVON-109 STUDY Fatemeh Saberi Hosnijeh Received Received
  1152-PS THE USE OF THE BCL-2 INHIBITOR IN CLL PATIENTS WHO PROGRESSED AFTER B-CELL-RECEPTOR INHIBITORS: A RETROSPECTIVE MULTICENTER ITALIAN EXPERIENCE Luca Laurenti Received Received
  1153-PS IMPACT OF COMORBIDITIES ON OUTCOMES OF THERAPY WITH IDELALISIB (IDELA), A PHOSPHOINOTISIDE-3 KINASE-DELTA INHIBITOR, IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Max Gordon Received Received
  1155-PS A PHASE I/II STUDY OF THE SYK INHIBITOR ENTOSPLETINIB IN COMBINATION WITH OBINUTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Alexey Danilov Received Received
  1171-PS TELOMERE LENGTH AT DIAGNOSIS OF CHRONIC MYELOID LEUKEMIA PREDICTS THE ACHIEVEMENT OF DEEP MOLECULAR RESPONSE TO IMATINIB Natalia Estrada Received Received
  1172-PS DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME Gioia Colafigli Received Received
  1175-PS DETECTING BCR-ABL AND SCORING MR: RESULTS FROM A CE-IVD KIT RUN ON NON-IVD PCR INSTRUMENTS: A COMPARISON WITH DATA FROM A EUTOS VALIDATED LAB. Jesper Petersen Received Received
  1179-PS TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS HARBOURING ATYPICAL BCR-ABL1 TRANSCRIPTS MATTEO DRAGANI Received Received
  1180-PS FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) Kiran Naqvi Received Received
  1184-PS ANALYSIS OF BCR-ABL1 TRANSCRIPT LEVELS AT 3 MONTHS IN PREDICTING OVERALL RESPONSE IN PATIENTS OF CHRONIC MYELOID LEUKEMIA- CHRONIC PHASE ON 1ST LINE THERAPY WITH IMATINIB MESYLATE Asif Iqbal Received Received
  1193-PS CHARACTERISTICS AND OUTCOMES OF THE TREATMENT PATIENTS WITH T315I MUTATION CML Julia Vlasova Received Received
  1196-PS INNOVATIVE DIAGNOSTIC APPROACH FOR RARE ANEMIA Valeria Rizzuto Received Received
  1197-PS ASSESSING THE EMA BINDING TEST AND OSMOTIC GRADIENT EKTACYTOMETRY IN THE DIAGNOSIS OF HEREDITARY SPHEROCYTOSIS DEFINED BY THE PRESENCE OF UNDERLYING DIAGNOSTIC MUTATIONS Andreas Glenthoej Received Received
  1203-PS HEREDITARY SPHEROCYTOSIS: SCREENING AND DIAGNOSTIC APPROACH IN A BELGIAN LABORATORY Edith Sepulchre Received Received
  1204-PS SEVERE HEREDITARY HAEMOLYTIC ANAEMIA DUE TO THREE NOVEL SPTA1 MUTATIONS IN TWO COMPOUND HETEROZYGOUS UNRELATED PATIENTS. Juan-Luis Vives-Corrons Received Received
  1214-PS INFECTIOUS COMPLICATIONS FOLLOWING ARI-0001 CELL (A3B1:CD8:4-1BB:CD3Z CART19) TREATMENT IN ADULT AND PEDIATRIC PATIENTS WITH CD19 RELAPSED / REFRACTORY MALIGNANCIES Valentín Ortiz-Maldonado Received Received
  1215-PS SAFETY AND TOLERABILITY OF ALLOGENEIC, OFF-THE SHELF PLACENTAL NATURAL KILLER CELLS (PNK 007) IN PHASE 1 MULTIPLE MYELOMA AND ACUTE MYELOID LEUKEMIA STUDIES (NCT02955550 AND NCT02781467) Sharmila Koppisetti Received Received
  1219-PS CAUSES OF NON ELIGIBILITY FOR CD19 CAR T-CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT-LOUIS HOSPITAL Jérme PAILLASSA Received Received
  1222-PS IL-6 ASSOCIATED WITH GRADING OF CYTOKINE RELEASE SYNDROME AND MANAGEMENT TIME OF TOCILIZUMAB AFTER CAR-T CELL THERAPY Heng Mei Received Received
  1237-PS DOSE DENSE ABVD (DD-ABVD) AS FIRST LINE THERAPY IN EARLY-STAGE UNFAVOURABLE HODGKIN LYMPHOMA (CHL): RESULTS OF A PHASE II, PROSPECTIVE, MULTI-CENTER STUDY BY FONDAZIONE ITALIANA LINFOMI Rita Mazza Received Received
  1254-PS CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA AFTER RETREATMENT WITH SECOND-LINE RITUXIMAB-CONTAINING CHEMOTHERAPY Jiajia Liu Received Received
  1255-PS EFFICACY OF R-BAC IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA POST BTK INHIBITOR THERAPY Rory McCulloch Received Received
  1258-PS CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS CHRISTINA KALPADAKIS Received Received
  1259-PS LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA Michinori Ogura Received Received
  1266-PS CLINICAL ASPECTS, MORPHOLOGICAL ANALYSIS AND IMMUNOHISTOCHEMICAL CHARACTERISTICS OF PATIENTS WITH FOLLICULAR LYMPHOMA IN DUODENUM BIOPSY: CASES WITH RESTRICT DISEASE VERSUS ADVANCED PRESENTATION. Guilherme Brasil Duffles Amarante Received Received
  1274-PS EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION INADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: ARETROSPECTIVE MONOCENTER STUDY Francesca Bettelli Received Received
  1276-PS EPIDEMIOLOGY AND CLINICAL OUTCOME OF FUNGAL INFECTIONS OF THE CENTRAL NERVOUS SYSTEM IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS. GABRIELE FACCHIN Received Received
  1284-PS GLOBAL GUIDELINE FOR THE DIAGNOSIS AND MANAGEMENT OF MUCORMYCOSIS: AN INITIATIVE OF THE ECMM IN COOPERATION WITH THE MSG ERC Kerstin Albus Received Received
  1289-PS THE ATYPICAL LYMPHOCYTE COUNT: A NOVEL PREDICTIVE FACTOR FOR SEVERE DENGUE INFECTION Visula Abeysuriya Received Received
  1292-PS LINK BETWEEN IRON AND TRYPTOPHAN METABOLISM OBSERVED IN INDIVIDUALS WITH IRON DEFICIENCY AND ANEMIA Dietmar Enko Received Received
  1300-PS A NURSE LED IRON INFUSION CLINIC IMPROVES PATIENT SAFETY AND REDUCES HEALTH CARE COSTS Laurie Newman Received Received
  1315-PS CHANGES IN THE SECRETOME COMPOSITION OF MULTIPOTENT MESENCHYMAL STROMAL CELLS PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA WITHOUT BONE MARROW INVOLVEMENT Nataliya Petinati Received Received
  1319-PS MYD88L265P MUTATION IN WM AND IGM-MGUS: COMPARISON OF FEASIBILITY AND BENEFIT BETWEEN DDPCR AND STANDARD ASQPCR IN CD19 SELECTED AND UNSELECTED SAMPLES Daniela Drandi Received Received
  1323-PS HIGH SERUM LEVELS OF IL-2R, IL-6, AND TNF ARE ASSOCIATED WITH HIGHER TUMOR BURDEN AND POORER OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA Pablo MOZAS Received Received
  1325-PS IDENTIFICATION AND TARGETING OF MOLECULAR SIGNATURES OF HYPOMETHYLATING AGENT RESISTANCE IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA Yue Wei Received Received
  1327-PS RIPK3 AS A STAGE-DEPENDENT MARKER IN THE BM OF PATIENTS WITH MDS AND CMML Veronika Dill Received Received
  1342-PS PREDICTING SURVIVAL AND TRANSFORMATION IN YOUNG AND MIDDLE-AGED PATIENTS WITH MYELODYSPLASTIC SYNDROME Natalia Klimkovich Received Received
  1345-PS CIRCULATING TUMOR DNA AS A LIQUID BIOPSY IN SMOLDERING MULTIPLE MYELOMA TO IDENTIFY BIOMARKERS OF PROGRESSION Martina Manzoni Received Received
  1354-PS MYELOMA-INDUCED MYELOID-DERIVED SUPPRESSOR CELLS ARE TARGETED BY IMMUNOMODULATORY DRUGS THAT REGULATE THE CCL5/CCR5 AXIS AND MIF AND IRF8 EXPRESSION Saeko Ota Received Received
  1360-PS LONG NON-CODING RNA NEAT1 TARGETING TRIGGERS ANTI-TUMOR ACTIVITY AND RESULTS IN CHEMO-SENSITIZING EFFECT IN MULTIPLE MYELOMA CELLS Elisa Taiana Received Received
  1367-PS COMPREHENSIVE GENETIC ANALYSIS OF MULTIPLE MYELOMA IN JAPAN Takashi Kanamori Received Received
  1368-PS IGH AND IGK REARRANGEMENT AND IGH SOMATIC HYPERMUTATION ANALYSIS USING NEXT-GENERATION SEQUENCING FOR THE DETECTION OF CLONALITY IN HIGH-RISK KOREAN MULTIPLE MYELOMA PATIENTS Young Kyung Lee Received Received
  1383-PS A SEQUENTIAL COHORT STUDY COMPARING KAPPAMAB ALONE TO KAPPAMAB, LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN KAPPA-RESTRICTED RELAPSED REFRACTORY (RR) MULTIPLE MYELOMA (AMARC 01-16) Anna Kalff Received Received
  1398-PS RECOVERY OF POLICLONAL IMMUNOGLOBULINS AS A PREDICTOR FACTOR OF INCREASED PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA INELIGIBLE FOR ASCT Julio Davila Received Received
  1402-PS OUTCOME IN TRANSPLANT ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA IN LATIN AMERICA. AN INTERNATIONAL STUDY OF GELAMM. Camila Peña Received Received
  1408-PS PROGNOSTIC SIGNIFICANCE OF CD56 EXPRESSION ON BONE MARROW PLASMA CELLS OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS. Giulia Rivoli Received Received
  1415-PS SURVIVAL OF MULTIPLE MYELOMA PATIENTS DIAGNOSED 1970-2015: REAL-WORLD DATA FROM A SINGLE CENTER Luis Gerardo Rodríguez-Lobato Received Received
  1423-PS NEXT-GENERATION SEQUENCING STUDY OF V(D)J REARRANGEMENTS ON NON-CR PATIENTS SHOWING MRD NEGATIVITY BY NEXT-GENERATION FLOW Kim Sung-Min Received Received
  1427-PS THE SIGNIFICANCE OF UNEXPECTED PHARMACOKINETICS OF DARATUMUMAB DURING LONG-TERM MONTHLY TREATMENT FOR MYELOMA Linda Little Received Received
  1435-PS SLAMF7 HIGH CD16 NEGATIVE MONOCYTES INCREASE IN PERIPHERAL BLOOD OF PATIENTS WITH MYELOFIBROSIS IN CORRELATION WITH JAK2V617F MUTATION Shoichiro Kato Received Received
  1436-PS IFN-? TREATMENT NORMALIZES THE PLATELET COUNTS AND REDUCES QUIESCENT STEM CELLS IN A CALR-DEL52 TRANSGENIC MOUSE MODEL, IN VIVO. Harini Nivarthi Received Received
  1438-PS DATA-DRIVEN ANALYSIS OF JAK2V617F KINETICS DURING INTERFERON-ALPHA2 TREATMENT OF PATIENTS WITH POLYCYTHEMIA VERA AND RELATED NEOPLASMS Vibe Skov Received Received
  1447-PS ANALYSIS OF UPR-RELATED GENE EXPRESSION IN CD34 CELLS FROM PATIENTS WITH PRIMARY MYELOFIBROSIS REVEALS DOWNREGULATION OF UPR GENES AND REDUCTION OF APOPTOSIS Paolo Catarsi Received Received
  1453-PS CURCUMIN INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN JAK2 MUTATED CELLS THROUGH THE INHIBITION OF JAK2/STAT AND MTORC1 PATHWAYS Jessica Petiti Received Received
  1458-PS RISK FACTORS AND OUTCOME OF ACUTE MYELOID LEUKEMIA SECONDARY TO POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: AN ANALYSIS OF THE MYSEC COHORT Barbara Mora Received Received
  1462-PS SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY Margherita Maffioli Received Received
  1466-PS CYTOREDUCTION FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: A SYSTEMATIC REVIEW Olivia Geen Received Received
  1470-PS EFFICACY AND SAFETY OF ANAGRELIDE IN OLDER PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA Veronika Buxhofer-Ausch Received Received
  1472-PS CURRENT PRACTICE IN MANAGEMENT OF ESSENTIAL THROMBOCYTEMIA AND POLYCYTHEMIA VERA: A SURVEY FROM THE FRENCH INTERGROUP OF MYELOPROLIFERATIVE NEOPLASMS (FIM) AMONG 120 HEMATOLOGISTS AND INTERNISTS Mathieu Wemeau Received Received
  1475-PS COATED PLATELET FUNCTION IS RELATED TO BLEEDING PHENOTYPE IN PATIENTS WITH INHERITED THROMBOCYTOPENIA Nanna Broens Received Received
  1476-PS APPLICATION OF WHOLE EXOME SEQUENCING FOR PATIENTS WITH INHERITED PLATELET DISORDERS Marian Stevens-Kroef Received Received
  1493-PS NEXT-GENERATION SEQUENCING REVEALS DISTINCT EXPANDED T-CELL RECEPTOR (TCR) B-CHAIN CLONOTYPES IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) Amna Malik Received Received
  1497-PS NEUTROPHIL EXTRACELLULAR TRAPS (NETS), BLOOD CELL COUNTS AND THROMBOTIC RISK IN ITP PATIENTS Maria L Lozano Received Received
  1499-PS THE EMOTIONAL IMPACT OF WATCH AND WAIT FOR CLL Lauren Walton Received Received
  1508-PS QUALITY OF LIFE AND PERCEPTION OF HEALTH CARE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES IN THE UK Sophie Wintrich Received Received
  1509-PS QoL IN PATIENTS WITH R/R MULTIPLE MYELOMA DURING IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION AND IXAZOMIB MAINTENANCE THERAPY AND COMPARISON TO THE GENERAL POPULATION Heinz Ludwig Received Received
  1511-PS THE FINANCIAL IMPACT OF ACUTE LEUKAEMIA Lauren Walton Received Received
  1512-PS THE DIAGNOSTIC YIELD OF BONE MARROW BIOPSY IN PATIENTS WITH LIVER FAILURE Thinzar Ko Ko Received Received
  1515-PS PREMEDICATION WITH MONTELUKAST AND RUPATADINE DECREASES INFUSION TIME, RATE AND SEVERITY OF REACTIONS AND OVERALL COST OF RITUXIMAB ADMINISTRATION Rouslan Kotchetkov Received Received
  1517-PS MILD COGNITIVE IMPAIRMENT, HYPOALBUMINEMIA, HIGH CRP AND GASTRO-INTESTINAL ULCER: 4 MARKERS OF FRAILTY WHICH IDENTIFY OLDER PATIENTS WITH MALIGNANT HEMOPATHIES WHO DONT BENEFIT FROM CHEMOTHERAPY VINCENT THIBAUD Received Received
  1530-PS POST-TRANSPLANT CYCLOPHOSPHAMIDE IN HLA MATCHED AND HAPLOIDENTICAL TRANSPLANT RECIPIENTS RECEIVING MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN CONDITIONING REGIMEN: RESULTS OF A PHASE II STUDY Rohtesh Mehta Received Received
  1534-PS EFFICACY AND SAFETY OF STEM CELL MOBILISATION FOLLOWING GDP SALVAGE IN PATIENTS WITH RELAPSED OR REFRACTORY LYMPHOMA Catherine Tang Received Received
  1535-PS AUTOLOGOUS STEM CELL TRANSPLANT FOLLOWED BY POST-TRANSPLANT IMMUNOTHERAPY WITH NIVOLUMAB AND UNSELECTED AUTOLOGOUS LYMPHOCYTES INFUSION AS SALVAGE THERAPY FOR RELAPSED/REFRACTORY HODGKIN LYMPHOMA Fabio Guolo Received Received
  1538-PS SAFETY OF HEMATOPOIETIC STEM CELL DONATION. RETROSPECTIVE ANALYSIS OF EARLY POST DONATION FOLLOW UP IN VOLUNTARY DONORS REGISTERED IN DKMS FOUNDATION DONOR CENTER, POLAND Tigran Torosian Received Received
  1551-PS INTENSIVE ORAL CARE CAN REDUCE BLOOD STREAM INFECTION POST NEUTROPHIL ENGRAFTMENT IN ALLOGENEIC HSCT Tatsuya Suwabe Received Received
  1561-PS RITUXIMAB-BEAM AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) FOR PATIENTS (PTS) WITH RELAPSED FOLLICULAR LYMPHOMA (FL) NOT ABLE TO RECEIVE AN ALLOGENEIC SCT: 8-YEAR MEDIAN FOLLOW-UP RESULTS. Issa Khouri Received Received
  1587-PS EDUCATIONAL INTERVENTION ENCOURAGING APPROPRIATE USE OF BLOOD TRANSFUSIONS EXTENDED FOLLOW UP AND COMPARATIVE STUDY Oren Pasvolsky Received Received
  1588-PS FIBRINOLYSIS IN PATIENTS WITH CHEMOTHERAPY INDUCED THROMBOCYTOPENIA AND THE EFFECT OF PLATELET TRANSFUSION. Floor Heubel-Moenen Received Received
  1592-PS EFFECT OF ANAEMIA ON MUSCLE OXYGEN SATURATION DURING EXERCISE Philip Crispin Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:30, Fri 8:30-15:00
23:39
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

EUROPEAN HEMATOLOGY ASSOCIATION

24th Congress of EHA

 

June 13-16, 2019 Amsterdam
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 13/06/2019 TO 13/06/2019
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                   DOI: 10.3252/pso.eu.24EHA.2019 
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 27/05/2019
Upload Poster
Upload Oral Presentation of Video
Check your Poster
Upload
Poster
Upload Oral
Presentation or Video
Check
your Poster




PosterSessionOnline
Logo Draft
 
Logo Cert